Marker Therapeutics (MRKR) Preferred Stock Liabilities (2014)
Marker Therapeutics (MRKR) posted quarterly Preferred Stock Liabilities of $10.0 million for Q4 2014.
Marker Therapeutics (MRKR) Preferred Stock Liabilities (2014) Analysis & Trends
Marker Therapeutics (MRKR) has reported Preferred Stock Liabilities for 1 consecutive years, with $10.0 million the latest figure, recorded in Q4 2014.
- In Q4 2014, Preferred Stock Liabilities changed N/A year-over-year to $10.0 million; the TTM figure through Dec 2014 stood at $10.0 million (changed N/A YoY), while the FY2014 annual figure was $10.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $10.0 million in Q4 2014 per MRKR's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $10.0 million in Q4 2014 and bottomed at $10.0 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 10.00 Mn |